A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.
about
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteChallenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy.Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution.An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response.T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein.Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapyCurrent and Potential Uses of Immunocytokines as Cancer Immunotherapy.Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.The role of inflammation in the pathogenesis of lung cancer.Using antibodies to target cancer therapeutics.Designing immunoconjugates for cancer therapy.Immunocytokines: a review of molecules in clinical development for cancer therapy.Synergistic immunologic targets for the treatment of prostate cancer.Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo.Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments.Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size.Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.Emerging classes of armed antibody therapeutics against cancerImmunocytokines
P2860
Q28066935-3D003261-69D8-4F4F-B32B-361826C7804EQ33811204-911D00FA-3A6A-4316-B230-DFDC22322EECQ35059990-1F9ED9C8-D6FC-4818-A000-1FC09412E291Q35212575-1CF505B7-D273-44B8-90AC-246BEEF07D5DQ35266959-18039014-15BA-4AE5-8BEC-854BC0719E5CQ36552580-2C7864BA-C913-46AA-8964-E5C09E1A86AAQ36696647-9D09D239-7AA7-49C2-B5F6-703B6349D84FQ37637949-ECDD68D8-132E-4453-90CD-0BB03EB8A280Q37741534-9CCE894F-B4F2-4FA3-92E1-43402DA468FEQ37900640-10A062FC-BB09-4AA1-8EEB-8F97FE66D8D3Q38014920-41AA2181-F54D-478C-AD7D-B939BCAF71FAQ38017203-24253394-22F6-4132-9F80-C734213A8172Q38132742-C9EFD6A7-E4F7-4815-A601-4CB6CDE6753FQ38904873-002D5501-C287-40D3-97F1-3A6631422260Q44703429-3670F82D-61F4-494F-A773-55B2CB374426Q50034069-23825256-DD9A-4EFA-90A0-C609080C0C4AQ51786117-4B1E7564-B5E9-43EB-8E67-D2DFC5CF70F2Q55162750-A13C1AF7-5A40-4C89-8551-AF45FFA28C21Q55316979-EC95A6A8-AA57-43C5-A2E4-EEE2C237EC4DQ57911948-C36423ED-D903-4534-858C-201AF1DFDE6EQ57911975-5B69564C-65BE-448A-9557-88FA808046CD
P2860
A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@en
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@nl
type
label
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@en
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@nl
prefLabel
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@en
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@nl
P2093
P1476
A low-toxicity IL-2-based immu ...... of IL-2 receptor selectivity.
@en
P2093
Beatrice Brunkhorst
Kin-Ming Lo
Stefan O Mueller
Stephen D Gillies
Thore Hettmann
Yaping Sun
P304
P356
10.1158/1078-0432.CCR-10-2921
P407
P577
2011-04-29T00:00:00Z